Equities research analysts expect Omnicell, Inc. (NASDAQ:OMCL) to post $0.69 earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Omnicell’s earnings, with the lowest EPS estimate coming in at $0.68 and the highest estimate coming in at $0.71. Omnicell reported earnings per share of $0.54 in the same quarter last year, which would suggest a positive year over year growth rate of 27.8%. The company is scheduled to report its next quarterly earnings report on Thursday, February 7th.
According to Zacks, analysts expect that Omnicell will report full year earnings of $2.01 per share for the current financial year, with EPS estimates ranging from $1.98 to $2.03. For the next year, analysts forecast that the firm will post earnings of $2.37 per share, with EPS estimates ranging from $2.21 to $2.49. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Omnicell.
A number of research firms have commented on OMCL. BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 28th. Craig Hallum lifted their target price on shares of Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Benchmark boosted their price objective on shares of Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a research report on Friday, October 5th. Wells Fargo & Co boosted their price objective on shares of Omnicell from $59.00 to $61.00 and gave the company a “market perform” rating in a research report on Monday. Finally, Oppenheimer boosted their price objective on shares of Omnicell from $71.00 to $73.00 and gave the company an “outperform” rating in a research report on Friday, October 26th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $69.86.
In other news, CFO Peter J. Kuipers sold 5,574 shares of the business’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $68.87, for a total transaction of $383,881.38. Following the completion of the sale, the chief financial officer now owns 51,542 shares of the company’s stock, valued at approximately $3,549,697.54. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director James T. Judson sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $68.90, for a total transaction of $344,500.00. Following the sale, the director now directly owns 34,952 shares of the company’s stock, valued at approximately $2,408,192.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,834 shares of company stock valued at $1,481,601. Insiders own 3.71% of the company’s stock.
Several hedge funds have recently modified their holdings of OMCL. Bank of Montreal Can bought a new position in Omnicell in the 2nd quarter worth $102,000. Virtu Financial LLC bought a new position in Omnicell in the 2nd quarter worth $204,000. Everence Capital Management Inc. bought a new position in Omnicell in the 3rd quarter worth $204,000. First Republic Investment Management Inc. bought a new position in Omnicell in the 2nd quarter worth $226,000. Finally, Jane Street Group LLC bought a new position in Omnicell in the 1st quarter worth $237,000. 98.80% of the stock is owned by hedge funds and other institutional investors.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Recommended Story: How can you know how many shares are floating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.